Pop star Zara Larsson has revealed she hopes her new will be a form of "escapism".
Pop star Zara Larsson has revealed she hopes her new will be a form of "escapism".
The High Low goes out on a high – podcasts of the weekPandora Sykes and Dolly Alderton bow out after four years hosting their hit show. Plus: fly-on-the-wall chats with Pharrell Williams, and an accessible look at the climate emergency
Pollutionwatch: toxic threat from wood burning and tyre dustSwiss study analyses different sources of air pollution – the fourth largest risk factor for early death
Radical reassessment needed to hit net zero emissions by 2050, says NAOWatchdog finds UK is projected to fail to meet targets aimed at achieving climate goal
‘He will be remembered as a hero’: Denzel Washington and Viola Davis on Chadwick BosemanThe late actor knew he had a terminal illness during the filming of Ma Rainey’s Black Bottom – and turned in an astonishing performance
UBS Group AG said on Friday it appointed Chief Operating Officer and President EMEA Sabine Keller-Busse as president of UBS Switzerland, while Iqbal Khan, co-president of global wealth management, will succeed Keller-Busse as president EMEA, in addition to his current role. Keller-Busse, who joined UBS in 2010 and was named Group COO in 2018, succeeds Axel P. Lehmann who has decided to step down from his current roles as president personal & corporate banking and president UBS Switzerland at the end of January 2021, and will leave the bank after a transition phase at the end of July, UBS said in a statement.
Selby won his second UK Championship title when he beat O’Sullivan.
ROTTERDAM, The Netherlands (4 December 2020) – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today announced the acquisition of two speciality distribution companies in Mexico, Millikan S.A. de C.V. (“Millikan”) and Banner Química S.A. de C.V. (“Banner Química”). “It has been a very active year for our IMCD Mexico team, and we are pleased to maintain our growth momentum with the acquisitions of Millikan and Banner Química in this important Latin American market,” said Marcus Jordan, Americas President, IMCD. “Both companies perfectly complement our existing operations in Mexico and strengthen our technical and commercial offering in a number of core market segments.” Both based in Mexico City, Millikan and Banner Química collectively generated a revenue of USD 15 million in 2019 and add 60 employees to the IMCD Mexico team. This latest development is preceded by the establishment of IMCD Mexico in April 2020, which serves the pharmaceuticals, food, nutrition, and personal care industries. “Joining IMCD puts our company on the global map and we are delighted to share a mutual desire to offer market differentiation through technical expertise and trend-based solutions for the customers we serve,” said Francisco Camacho, General Director, Millikan. Millikan was established in 1998 and offers technical support and commercial expertise to customers in the food, nutrition, pharmaceuticals, and industrial markets. “I anticipate that IMCD’s reputation for professionalism and market proficiency will create new opportunities for innovation and growth for our loyal customers and principal partners,” said Salvador Ramos, General Director, Banner Química. Banner Química has delivered formulatory solutions for the personal care and home care industries since 2009. The acquisition of Millikan and Banner Química also enhances IMCD’s technical capabilities through the addition of its food and personal care laboratories, further strengthening IMCD’s global network of technical centres. -xxx- Attached, please find the release in pdf format. Attachment Press Release-IMCD Mexico continues growth momentum with acquisition of Millikan and Banner Química
Preliminary data from the Phase 1 trial are expected first half 2021Additional €3.4 million in non-dilutive funding from SPW-Recherche of the Walloon Region to support advancement of CYAD-211 MONT-SAINT-GUIBERT, Belgium, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced dosing of the first patient of the Phase 1 IMMUNICY-1 trial of CYAD-211, the Company’s novel, short hairpin RNA (shRNA)-based anti-B-cell maturation antigen (BCMA) candidate for the treatment of relapsed/refractory multiple myeloma (r/r MM). “Despite the introduction of several new treatment options over the past few years, multiple myeloma remains a devastating disease with a high unmet need for new therapies. We are proud to participate in the IMMUNICY-1 trial which will evaluate CYAD-211 in the treatment of relapsed or refractory multiple myeloma patients,” said professor Dr. Sébastien Anguille, CAR T specialist at the Antwerp University Hospital (UZA), Edegem, Belgium. “Based on the encouraging preclinical data, we believe this new allogeneic CAR T targeting BCMA has the potential to become an important therapy for such a challenging patient population.” Frédéric Lehmann, VP of Clinical Development & Medical Affairs at Celyad Oncology, added, “Dosing the first patient with CYAD-211 marks another major milestone to systematically advance our pipeline of non-gene edited allogeneic CAR T candidates. BCMA is highly expressed in multiple myeloma patients and we hope to see a positive clinical benefit with our approach of targeting BCMA with our first-in-class CAR T which is underpinned by our shRNA technology. Enrollment in the IMMUNICY-1 trial will continue over the coming months and we expect to report proof-of-concept data from the initial dose cohorts of the trial during the first half of 2021.” Financial Update The Company received €3.4 million in non-dilutive funding from the SPW-Recherche of the Walloon Region, which will support the development of CYAD 211. Under the terms of this funding, the Company was awarded non-dilutive funding in the form of recoverable cash advances (‘avances récupérables’). The regional funding is associated with the Company’s specific research and development programs. Under the applicable conditions, the recoverable cash advance is reimbursable over the economic life of the projects. Thirty percent is refundable based on a fixed reimbursement schedule of 20 years, while the balance is refunded under the form of royalties over the same period. The Company confirms its previous guidance that its existing treasury position should be sufficient, based on the current scope of activities, to fund operating expenses and capital expenditure requirements into the third quarter of 2021. About CYAD-211 CYAD-211 is an investigational, shRNA-based allogeneic CAR T candidate for the treatment of r/r MM. CYAD-211 is engineered to co-express a BCMA targeting chimeric antigen receptor and a single shRNA, which interferes with the expression of the CD3ζ component of the T cell receptor complex. In July 2020, Celyad Oncology announced FDA clearance of its IND application for CYAD-211. About IMMUNICY-1 Phase 1 Trial The open-label, dose-escalation trial will evaluate the safety and clinical activity of a single infusion of CYAD-211 following preconditioning chemotherapy cyclophosphamide (300 mg/m²) and fludarabine (30 mg/m²) in patients with relapse or refractory multiple myeloma. The trial will evaluate multiple dose levels of CYAD-211: 3x107, 1x108 and 3x108 cells per infusion. For more information, please visit www.clinicaltrials.gov, study identifier number NCT04613557. About shRNA Platform Celyad Oncology is focused on the development of its proprietary non-gene edited allogeneic shRNA technology platform. The shRNA platform coupled with the Company’s All-in-One vector approach provides flexibility, versatility, and efficiency to the design of novel, off-the-shelf CAR T candidates through a single step engineering process. Next-generation candidates exploring the breadth and depth of the Celyad Oncology shRNA platform are currently under preclinical development. In 2018, Celyad Oncology signed an exclusive agreement with Horizon Discovery Group for the use of its SMARTvector shRNA technology for the development of allogeneic CAR T therapies. About Celyad Oncology Celyad Oncology is a clinical-stage biotechnology company focused on the discovery and development of CAR T therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com. Forward-Looking Statement This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may include statements regarding: the clinical development of CYAD-211 and timing of expected data from the Phase 1 IMMUNICY-1 trial and the expected use of the non-dilutive funding from the Walloon Region. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty includes the duration and severity of the COVID-19 pandemic and government measures implemented in response thereto. A further list and description of these risks, uncertainties and other risks can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in its Annual Report on Form 20-F filed with the SEC on March 25, 2020 and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation. Investor and Media Contacts: Sara ZelkovicDirector Communications & Investor Relations Celyad Oncology firstname.lastname@example.org Daniel FerryManaging DirectorLifeSci Advisors, LLCdaniel@lifesciadvisors.com Source: Celyad Oncology SA
World Bank ‘missed vital opportunities’ to support Covid response, says OxfamMillions forced to do without or pay for services as funding fails to adequately shore up healthcare systems, report finds * Coronavirus – latest updates * See all our coronavirus coverage
Coalition IR changes would allow bosses to change workers' hours, duties and location. Christian Porter will unveil the reforms, including part-time flexibility provisions, next week
The WTA is planning to start the 2021 season in the first week of January outside Australia before the players travel to Melbourne for quarantine ahead of the Grand Slam, women's tour chief Steve Simon told Reuters. The Australian Open looks likely to be pushed back from its scheduled Jan. 18 start as Tennis Australia (TA) continue talks with local government over COVID-19 protocols to be established for Melbourne Park. Negotiations over when the players arrive in Australia and what they will be allowed to do during their 14 days of quarantine have dragged out over the last few weeks but Simon was confident the tournament would go ahead.
The Breaking Bad star revealed he had coronavirus in July.
The sister of a Thai pro-democracy activist who rights groups say was abducted by unknown gunmen in Cambodia called on Friday for authorities to solve the case after holding a Buddhist prayer ceremony to mark six months since his disappearance. Wanchalearm Satsaksit, 37, was bundled into a vehicle in front of his Phnom Penh apartment in June, New York-based Human Rights Watch said. Cambodian police have previously said they were unaware a kidnapping had taken place.
Tucker Carlson claims public health experts and the politicians who listen to them are trying to cancel Christmas.
The first batch of the Pfizer/BioNTech coronavirus vaccine is set to be distributed after arriving in the UK. Britain is fighting back against global criticism of its rapid approval of the vaccine, as the government tries to prevent damage to public confidence in the jab. Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases, claimed the fast decision could make people reluctant to get vaccinated.
Ian Taylor has helped bring the America's Cup to life for TV viewers since 1992 but he is slightly worried that the secret designs and sheer speed of the boats for next year's regatta may have left his computer graphics company in the dark. "We're testing all the data and software from next week," Animation Research's Taylor told Reuters by telephone from Dunedin. Animation Research's graphics have been credited by sailing commentators with helping the casual fan follow the event, with the package showing real-time animations of racing.
Snakes have found a safe space in Myanmar - a global hub for the illegal wildlife trade. For five years, this Buddhist temple in the city of Yangon has been taking in pythons and cobras and vipers otherwise destined for the black market. The sanctuary is run by Wilatha, a monk at the temple. "I always check on their health every morning. I feel from the bottom of my heart that they are my sons and daughters." The snakes are usually caught in or near homes, brought here by members of the community. According to Buddhist beliefs, saving a life will earn them 'merit,' though Wilatha's mission has an environmental angle, as well. "If I don't save these snakes and shelter them here, these snakes will be sold off in the black market. If so, the python would be extinct in Myanmar in the future. I believe that losing even one animal species will cause problems to nature. Even though we don't know specifically about their benefit to nature, the species are helping our environment." Conservationists say snakes are often smuggled to neighboring countries like China and Thailand, where they're eaten or used to make traditional medicine. The International Union for Conservation of Nature has sounded the alarm about their shrinking numbers, listing the Burmese python as "vulnerable" in Southeast Asia. Wilatha has made it part of his job to get the residents of his sanctuary back to the wild. Working with the forest authority, he releases those he feels are ready, hoping they are never caught again.
Maine has already denied the bizarre allegations as having ‘no validity’
Recently retired pro handed Europe-based, part-time position
Meeting the UK's legal target to cut emissions to net zero to curb climate change is a "colossal challenge", the National Audit Office (NAO) has warned, with people needing to eat less meat and drive electric cars to achieve it. The UK has enshrined the goal to reach net zero emissions by 2050 in law, which means cutting greenhouse gases as much as possible and offsetting remaining pollution by planting trees or using technology to capture carbon. In a report looking at the Government's arrangements for achieving net zero, the official spending watchdog warned it was significantly more challenging than the previous target to cut emissions by 80% by mid century - which the UK is not on track to meet. The NAO said the costs of achieving net zero were highly uncertain. But the costs of failing to act would be far greater because of the need to adapt to substantial changes in climate, such as building flood defences and dealing with the impacts on health of higher temperatures, the report said. The NAO also said the Government needs to spearhead a "concerted national effort" to achieve net zero, which would be likely to involve widespread changes to people's lives such as driving electric cars or eating less meat.